ID   ABL2_HUMAN              Reviewed;        1182 AA.
AC   P42684; A0M8X0; B7UEF2; B7UEF3; B7UEF4; B7UEF5; Q5T0X6; Q5W0C5;
AC   Q6NZY6; Q7Z301;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Abelson tyrosine-protein kinase 2;
DE            EC=2.7.10.2;
DE   AltName: Full=Abelson murine leukemia viral oncogene homolog 2;
DE   AltName: Full=Abelson-related gene protein;
DE   AltName: Full=Tyrosine-protein kinase ARG;
GN   Name=ABL2; Synonyms=ABLL, ARG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND ALTERNATIVE SPLICING
RP   (ISOFORM 2).
RX   PubMed=2198571; DOI=10.1073/pnas.87.15.5802;
RA   Kruh G.D., Perego R., Miki T., Aaronson S.A.;
RT   "The complete coding sequence of arg defines the Abelson subfamily of
RT   cytoplasmic tyrosine kinases.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5802-5806(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4; 5; 6 AND 7), ALTERNATIVE
RP   SPLICING (ISOFORM 10), AND VARIANT THR-12 (ISOFORM 4).
RX   PubMed=18810762; DOI=10.1002/jcb.21922;
RA   Bianchi C., Torsello B., Angeloni V., Bombelli S., Soldi M.,
RA   Invernizzi L., Brambilla P., Perego R.A.;
RT   "Eight full-length abelson related gene (Arg) isoforms are
RT   constitutively expressed in caki-1 cell line and cell distribution of
RT   two isoforms has been analyzed after transfection.";
RL   J. Cell. Biochem. 105:1219-1227(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 8).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Uterine endothelium;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-930; MET-946;
RP   ARG-996; ASN-1085 AND ALA-1101.
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 343-469.
RX   PubMed=3787260; DOI=10.1126/science.3787260;
RA   Kruh G.D., King C.R., Kraus M.H., Popescu N.C., Amsbaugh S.C.,
RA   McBride W.O., Aaronson S.A.;
RT   "A novel human gene closely related to the abl proto-oncogene.";
RL   Science 234:1545-1548(1986).
RN   [10]
RP   PHOSPHORYLATION AT TYR-272; TYR-439; TYR-568 AND TYR-683, AND ENZYME
RP   REGULATION.
RX   PubMed=12748290; DOI=10.1128/MCB.23.11.3884-3896.2003;
RA   Tanis K.Q., Veach D., Duewel H.S., Bornmann W.G., Koleske A.J.;
RT   "Two distinct phosphorylation pathways have additive effects on Abl
RT   family kinase activation.";
RL   Mol. Cell. Biol. 23:3884-3896(2003).
RN   [11]
RP   INTERACTION WITH RIN1, FUNCTION, AND ENZYME REGULATION.
RX   PubMed=15886098; DOI=10.1016/j.cub.2005.03.049;
RA   Hu H., Bliss J.M., Wang Y., Colicelli J.;
RT   "RIN1 is an ABL tyrosine kinase activator and a regulator of
RT   epithelial-cell adhesion and migration.";
RL   Curr. Biol. 15:815-823(2005).
RN   [12]
RP   FUNCTION, PHOSPHORYLATION AT TYR-261, AND UBIQUITINATION.
RX   PubMed=15735735; DOI=10.1038/sj.onc.1208454;
RA   Cao C., Li Y., Leng Y., Li P., Ma Q., Kufe D.;
RT   "Ubiquitination and degradation of the Arg tyrosine kinase is
RT   regulated by oxidative stress.";
RL   Oncogene 24:2433-2440(2005).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH PSMA7.
RX   PubMed=16678104; DOI=10.1016/j.molcel.2006.04.007;
RA   Liu X., Huang W., Li C., Li P., Yuan J., Li X., Qiu X.B., Ma Q.,
RA   Cao C.;
RT   "Interaction between c-Abl and Arg tyrosine kinases and proteasome
RT   subunit PSMA7 regulates proteasome degradation.";
RL   Mol. Cell 22:317-327(2006).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [15]
RP   FUNCTION.
RX   PubMed=17306540; DOI=10.1016/j.cub.2007.01.057;
RA   Boyle S.N., Michaud G.A., Schweitzer B., Predki P.F., Koleske A.J.;
RT   "A critical role for cortactin phosphorylation by Abl-family kinases
RT   in PDGF-induced dorsal-wave formation.";
RL   Curr. Biol. 17:445-451(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-817, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   FUNCTION.
RX   PubMed=18945674; DOI=10.1074/jbc.M804543200;
RA   Yogalingam G., Pendergast A.M.;
RT   "Abl kinases regulate autophagy by promoting the trafficking and
RT   function of lysosomal components.";
RL   J. Biol. Chem. 283:35941-35953(2008).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=12775773; DOI=10.1242/jcs.00622;
RA   Woodring P.J., Hunter T., Wang J.Y.;
RT   "Regulation of F-actin-dependent processes by the Abl family of
RT   tyrosine kinases.";
RL   J. Cell Sci. 116:2613-2626(2003).
RN   [19]
RP   REVIEW ON FUNCTION.
RX   PubMed=14729179; DOI=10.1016/j.tcb.2003.11.003;
RA   Hernandez S.E., Krishnaswami M., Miller A.L., Koleske A.J.;
RT   "How do Abl family kinases regulate cell shape and movement?";
RL   Trends Cell Biol. 14:36-44(2004).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-275 AND SER-915, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-633;
RP   SER-655; SER-817; SER-820 AND SER-936, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=18182299; DOI=10.1016/j.tibs.2007.10.006;
RA   Backert S., Feller S.M., Wessler S.;
RT   "Emerging roles of Abl family tyrosine kinases in microbial
RT   pathogenesis.";
RL   Trends Biochem. Sci. 33:80-90(2008).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-718, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT TYR-668 (ISOFORM 10), PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT TYR-647 (ISOFORM 4), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT TYR-683 (ISOFORM 5), PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT TYR-662 (ISOFORM 7), AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [25]
RP   IDENTIFICATION IN A COMPLEX WITH UNC119: ABL1 AND CRK.
RX   PubMed=19381274; DOI=10.1371/journal.pone.0005211;
RA   Vepachedu R., Karim Z., Patel O., Goplen N., Alam R.;
RT   "Unc119 protects from Shigella infection by inhibiting the Abl family
RT   kinases.";
RL   PLoS ONE 4:E5211-E5211(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-820 AND SER-936, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631 AND SER-936, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   REVIEW ON FUNCTION, AND DOMAIN.
RX   PubMed=20841568; DOI=10.1126/scisignal.3139re6;
RA   Colicelli J.;
RT   "ABL tyrosine kinases: evolution of function, regulation, and
RT   specificity.";
RL   Sci. Signal. 3:RE6-RE6(2010).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-631, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620; SER-631; SER-655;
RP   SER-671; SER-783; SER-817; SER-820 AND SER-936, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-620 AND SER-631, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [32]
RP   STRUCTURE BY NMR OF 163-268.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the human ABL2 SH2 domain.";
RL   Submitted (FEB-2008) to the PDB data bank.
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 279-546 IN COMPLEXES WITH
RP   INHIBITORS.
RX   PubMed=21417343; DOI=10.1021/jm101506n;
RA   Salah E., Ugochukwu E., Barr A.J., von Delft F., Knapp S.,
RA   Elkins J.M.;
RT   "Crystal structures of ABL-related gene (ABL2) in complex with
RT   imatinib, tozasertib (VX-680), and a type I inhibitor of the triazole
RT   carbothioamide class.";
RL   J. Med. Chem. 54:2359-2367(2011).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 563-579 IN COMPLEX WITH
RP   CTTN, AND INTERACTION WITH CTTN.
RX   PubMed=22297987; DOI=10.1107/S1744309111056132;
RA   Liu W., MacGrath S.M., Koleske A.J., Boggon T.J.;
RT   "Lysozyme contamination facilitates crystallization of a
RT   heterotrimeric cortactin-Arg-lysozyme complex.";
RL   Acta Crystallogr. F 68:154-158(2012).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-78; GLN-99; ILE-519; SER-769;
RP   ARG-930 AND ARG-996, AND VARIANT [LARGE SCALE ANALYSIS] THR-12
RP   (ISOFORM 4).
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor tyrosine-protein kinase that plays an ABL1-
CC       overlapping role in key processes linked to cell growth and
CC       survival such as cytoskeleton remodeling in response to
CC       extracellular stimuli, cell motility and adhesion and receptor
CC       endocytosis. Coordinates actin remodeling through tyrosine
CC       phosphorylation of proteins controlling cytoskeleton dynamics like
CC       MYH10 (involved in movement); CTTN (involved in signaling); or
CC       TUBA1 and TUBB (microtubule subunits). Binds directly F-actin and
CC       regulates actin cytoskeletal structure through its F-actin-
CC       bundling activity. Involved in the regulation of cell adhesion and
CC       motility through phosphorylation of key regulators of these
CC       processes such as CRK, CRKL, DOK1 or ARHGAP35. Adhesion-dependent
CC       phosphorylation of ARHGAP35 promotes its association with RASA1,
CC       resulting in recruitment of ARHGAP35 to the cell periphery where
CC       it inhibits RHO. Phosphorylates multiple receptor tyrosine kinases
CC       like PDGFRB and other substrates which are involved in endocytosis
CC       regulation such as RIN1. In brain, may regulate neurotransmission
CC       by phosphorylating proteins at the synapse. ABL2 acts also as a
CC       regulator of multiple pathological signaling cascades during
CC       infection. Pathogens can highjack ABL2 kinase signaling to
CC       reorganize the host actin cytoskeleton for multiple purposes, like
CC       facilitating intracellular movement and host cell exit. Finally,
CC       functions as its own regulator through autocatalytic activity as
CC       well as through phosphorylation of its inhibitor, ABI1.
CC       {ECO:0000269|PubMed:15735735, ECO:0000269|PubMed:15886098,
CC       ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:17306540,
CC       ECO:0000269|PubMed:18945674}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC   -!- ENZYME REGULATION: Stabilized in the inactive form by an
CC       association between the SH3 domain and the SH2-TK linker region,
CC       interactions of the N-terminal cap, and contributions from an N-
CC       terminal myristoyl group and phospholipids. Activated by
CC       autophosphorylation as well as by SRC-family kinase-mediated
CC       phosphorylation. Activated by RIN1 binding to the SH2 and SH3
CC       domains. Inhibited by imatinib mesylate (Gleevec) which is used
CC       for the treatment of chronic myeloid leukemia (CML).
CC       Phosphatidylinositol 4,5-bisphosphate (PIP2), a highly abundant
CC       phosphoinositide known to regulate cytoskeletal and membrane
CC       proteins, inhibits the tyrosine kinase activity (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with PSMA7. Interacts with CTTN. Found in a
CC       complex with ABL1, ABL2, CRK and UNC119; leading to the inhibition
CC       of CRK phosphorylation by ABL kinases.
CC       {ECO:0000269|PubMed:15886098, ECO:0000269|PubMed:16678104,
CC       ECO:0000269|PubMed:19381274, ECO:0000269|PubMed:22297987}.
CC   -!- INTERACTION:
CC       Q8IZP0:ABI1; NbExp=2; IntAct=EBI-1102694, EBI-375446;
CC       P46108:CRK; NbExp=5; IntAct=EBI-1102694, EBI-886;
CC       P00533:EGFR; NbExp=8; IntAct=EBI-1102694, EBI-297353;
CC       P04626:ERBB2; NbExp=6; IntAct=EBI-1102694, EBI-641062;
CC       P21860:ERBB3; NbExp=10; IntAct=EBI-1102694, EBI-720706;
CC       Q15303:ERBB4; NbExp=4; IntAct=EBI-1102694, EBI-80371;
CC       P06241:FYN; NbExp=2; IntAct=EBI-1102694, EBI-515315;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-1102694, EBI-401755;
CC       P10721:KIT; NbExp=2; IntAct=EBI-1102694, EBI-1379503;
CC       P16333:NCK1; NbExp=4; IntAct=EBI-1102694, EBI-389883;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-1102694, EBI-79464;
CC       P19174:PLCG1; NbExp=4; IntAct=EBI-1102694, EBI-79387;
CC       Q13671:RIN1; NbExp=4; IntAct=EBI-1102694, EBI-366017;
CC       Q15637:SF1; NbExp=3; IntAct=EBI-1102694, EBI-744603;
CC       P12931:SRC; NbExp=2; IntAct=EBI-1102694, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC       Name=1; Synonyms=IB, 1BLCTL;
CC         IsoId=P42684-1; Sequence=Displayed;
CC       Name=2; Synonyms=IA, 1ASCTL;
CC         IsoId=P42684-2; Sequence=VSP_004961;
CC       Name=3; Synonyms=IC, 1ALCTL;
CC         IsoId=P42684-3; Sequence=VSP_017112;
CC       Name=4; Synonyms=1ASCTS;
CC         IsoId=P42684-4; Sequence=VSP_004961, VSP_021308;
CC         Note=Variant in position: 12:S->T (in dbSNP:rs1318056). Contains
CC         a phosphotyrosine at position 647.
CC         {ECO:0000244|PubMed:19369195};
CC       Name=5; Synonyms=1BLCTS;
CC         IsoId=P42684-5; Sequence=VSP_021308;
CC         Note=Contains a phosphotyrosine at position 683.
CC         {ECO:0000244|PubMed:19369195};
CC       Name=6; Synonyms=1BSCTL;
CC         IsoId=P42684-6; Sequence=VSP_041772;
CC       Name=7; Synonyms=1BSCTS;
CC         IsoId=P42684-7; Sequence=VSP_041772, VSP_021308;
CC         Note=Contains a phosphotyrosine at position 662.
CC         {ECO:0000244|PubMed:19369195};
CC       Name=10; Synonyms=1ALCTS;
CC         IsoId=P42684-10; Sequence=VSP_017112, VSP_021308;
CC         Note=Contains a phosphotyrosine at position 668.
CC         {ECO:0000244|PubMed:19369195};
CC       Name=8;
CC         IsoId=P42684-8; Sequence=VSP_041772, VSP_041773, VSP_041774;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed.
CC   -!- DOMAIN: Contains two distinct classes of F-actin-binding domains.
CC       Although both can bind F-actin, the 2 are required to bundle actin
CC       filaments (By similarity). {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Tyr-261 by ABL1 in response to oxidative
CC       stress. Phosphorylated by PDGFRB (By similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated. Polyubiquitination of ABL2 leads to
CC       degradation. {ECO:0000269|PubMed:15735735}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. ABL subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD98092.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ABL2ID226.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/abl2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M35296; AAA35553.1; -; mRNA.
DR   EMBL; FJ542283; ACK76601.1; -; mRNA.
DR   EMBL; FJ542284; ACK76602.1; -; mRNA.
DR   EMBL; FJ542285; ACK76603.1; -; mRNA.
DR   EMBL; FJ542286; ACK76604.1; -; mRNA.
DR   EMBL; AK311045; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BX538317; CAD98092.1; ALT_INIT; mRNA.
DR   EMBL; DQ009672; AAY16984.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAH70921.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAH70921.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAH70921.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAH70925.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAH70925.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAH70925.1; JOINED; Genomic_DNA.
DR   EMBL; AL359179; CAI15584.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAI15584.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI15584.1; JOINED; Genomic_DNA.
DR   EMBL; AL359179; CAI15585.1; -; Genomic_DNA.
DR   EMBL; AL139132; CAI15585.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI15585.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI13566.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAI13566.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAI13566.1; JOINED; Genomic_DNA.
DR   EMBL; AL512326; CAI13570.1; -; Genomic_DNA.
DR   EMBL; AL359179; CAI13570.1; JOINED; Genomic_DNA.
DR   EMBL; AL139132; CAI13570.1; JOINED; Genomic_DNA.
DR   EMBL; CH471067; EAW91040.1; -; Genomic_DNA.
DR   EMBL; BC065912; AAH65912.1; -; mRNA.
DR   CCDS; CCDS30947.1; -. [P42684-1]
DR   CCDS; CCDS41441.2; -. [P42684-3]
DR   CCDS; CCDS44282.1; -. [P42684-10]
DR   CCDS; CCDS44283.1; -. [P42684-8]
DR   CCDS; CCDS53435.1; -. [P42684-4]
DR   CCDS; CCDS53436.1; -. [P42684-6]
DR   CCDS; CCDS53437.1; -. [P42684-7]
DR   CCDS; CCDS53438.1; -. [P42684-5]
DR   PIR; A35962; A35962.
DR   PIR; B35962; B35962.
DR   RefSeq; NP_001129472.1; NM_001136000.2. [P42684-10]
DR   RefSeq; NP_001129473.1; NM_001136001.1. [P42684-8]
DR   RefSeq; NP_001161708.1; NM_001168236.1. [P42684-6]
DR   RefSeq; NP_001161709.1; NM_001168237.1. [P42684-5]
DR   RefSeq; NP_001161710.1; NM_001168238.1. [P42684-7]
DR   RefSeq; NP_001161711.1; NM_001168239.1. [P42684-4]
DR   RefSeq; NP_005149.4; NM_005158.4. [P42684-3]
DR   RefSeq; NP_009298.1; NM_007314.3. [P42684-1]
DR   RefSeq; XP_005245145.1; XM_005245088.2. [P42684-2]
DR   UniGene; Hs.159472; -.
DR   PDB; 2ECD; NMR; -; A=163-268.
DR   PDB; 2KK1; NMR; -; A=1058-1182.
DR   PDB; 2XYN; X-ray; 2.81 A; A/B/C=279-546.
DR   PDB; 3GVU; X-ray; 2.05 A; A=279-546.
DR   PDB; 3HMI; X-ray; 1.65 A; A=279-546.
DR   PDB; 3ULR; X-ray; 1.65 A; C=563-579.
DR   PDB; 4EIH; X-ray; 1.20 A; A=165-273.
DR   PDBsum; 2ECD; -.
DR   PDBsum; 2KK1; -.
DR   PDBsum; 2XYN; -.
DR   PDBsum; 3GVU; -.
DR   PDBsum; 3HMI; -.
DR   PDBsum; 3ULR; -.
DR   PDBsum; 4EIH; -.
DR   ProteinModelPortal; P42684; -.
DR   SMR; P42684; -.
DR   BioGrid; 106545; 40.
DR   DIP; DIP-91N; -.
DR   IntAct; P42684; 42.
DR   MINT; MINT-1347081; -.
DR   STRING; 9606.ENSP00000427562; -.
DR   BindingDB; P42684; -.
DR   ChEMBL; CHEMBL4014; -.
DR   DrugBank; DB00171; Adenosine triphosphate.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB05184; XL228.
DR   GuidetoPHARMACOLOGY; 1924; -.
DR   iPTMnet; P42684; -.
DR   PhosphoSitePlus; P42684; -.
DR   BioMuta; ABL2; -.
DR   DMDM; 1168268; -.
DR   EPD; P42684; -.
DR   MaxQB; P42684; -.
DR   PaxDb; P42684; -.
DR   PeptideAtlas; P42684; -.
DR   PRIDE; P42684; -.
DR   DNASU; 27; -.
DR   Ensembl; ENST00000344730; ENSP00000339209; ENSG00000143322. [P42684-10]
DR   Ensembl; ENST00000367623; ENSP00000356595; ENSG00000143322. [P42684-6]
DR   Ensembl; ENST00000392043; ENSP00000375897; ENSG00000143322. [P42684-8]
DR   Ensembl; ENST00000502732; ENSP00000427562; ENSG00000143322. [P42684-1]
DR   Ensembl; ENST00000504405; ENSP00000426831; ENSG00000143322. [P42684-4]
DR   Ensembl; ENST00000507173; ENSP00000423413; ENSG00000143322. [P42684-7]
DR   Ensembl; ENST00000511413; ENSP00000424697; ENSG00000143322. [P42684-5]
DR   Ensembl; ENST00000512653; ENSP00000423578; ENSG00000143322. [P42684-3]
DR   GeneID; 27; -.
DR   KEGG; hsa:27; -.
DR   UCSC; uc001gmg.5; human. [P42684-1]
DR   CTD; 27; -.
DR   DisGeNET; 27; -.
DR   GeneCards; ABL2; -.
DR   HGNC; HGNC:77; ABL2.
DR   HPA; CAB017106; -.
DR   HPA; HPA001866; -.
DR   MIM; 164690; gene.
DR   neXtProt; NX_P42684; -.
DR   OpenTargets; ENSG00000143322; -.
DR   PharmGKB; PA24414; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118938; -.
DR   HOVERGEN; HBG004162; -.
DR   InParanoid; P42684; -.
DR   KO; K08887; -.
DR   OMA; VDTGHQL; -.
DR   OrthoDB; EOG091G0D46; -.
DR   PhylomeDB; P42684; -.
DR   TreeFam; TF105081; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-428890; Role of Abl in Robo-Slit signaling.
DR   SignaLink; P42684; -.
DR   SIGNOR; P42684; -.
DR   ChiTaRS; ABL2; human.
DR   EvolutionaryTrace; P42684; -.
DR   GeneWiki; ABL2; -.
DR   GenomeRNAi; 27; -.
DR   PRO; PR:P42684; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143322; -.
DR   CleanEx; HS_ABL2; -.
DR   Genevisible; P42684; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0051015; F:actin filament binding; TAS:UniProtKB.
DR   GO; GO:0003785; F:actin monomer binding; TAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0001784; F:phosphotyrosine binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IBA:GO_Central.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IMP:MGI.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0051353; P:positive regulation of oxidoreductase activity; IDA:BHF-UCL.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IMP:MGI.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; TAS:UniProtKB.
DR   GO; GO:0010506; P:regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IBA:GO_Central.
DR   GO; GO:0030100; P:regulation of endocytosis; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR015015; F-actin_binding.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF08919; F_actin_bind; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00808; FABD; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell adhesion; Complete proteome; Cytoplasm; Cytoskeleton; Kinase;
KW   Lipoprotein; Magnesium; Manganese; Metal-binding; Myristate;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   SH2 domain; SH3 domain; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed.
FT   CHAIN         2   1182       Abelson tyrosine-protein kinase 2.
FT                                /FTId=PRO_0000088052.
FT   DOMAIN      107    167       SH3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN      173    263       SH2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00191}.
FT   DOMAIN      288    539       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     294    302       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     362    368       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        2    106       CAP.
FT   REGION      694    930       F-actin-binding. {ECO:0000250}.
FT   REGION     1020   1182       F-actin-binding. {ECO:0000250}.
FT   MOTIF       427    451       Kinase activation loop. {ECO:0000250}.
FT   MOTIF       658    660       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   COMPBIAS    561    564       Poly-Ser.
FT   COMPBIAS    732    739       Poly-Gly.
FT   COMPBIAS    843   1055       Pro-rich.
FT   COMPBIAS    984    988       Poly-Pro.
FT   ACT_SITE    409    409       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     317    317       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      97     97       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     116    116       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     161    161       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     174    174       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     185    185       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     218    218       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     231    231       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     261    261       Phosphotyrosine; by ABL1 and
FT                                autocatalysis.
FT                                {ECO:0000269|PubMed:15735735}.
FT   MOD_RES     272    272       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12748290}.
FT   MOD_RES     275    275       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     299    299       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     303    303       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     439    439       Phosphotyrosine; by autocatalysis and
FT                                SRC-type Tyr-kinases.
FT                                {ECO:0000269|PubMed:12748290}.
FT   MOD_RES     459    459       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     492    492       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00520}.
FT   MOD_RES     568    568       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12748290}.
FT   MOD_RES     620    620       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     631    631       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     633    633       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     655    655       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     669    669       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     670    670       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     671    671       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     683    683       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12748290}.
FT   MOD_RES     718    718       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     776    776       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     783    783       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     800    800       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P00519}.
FT   MOD_RES     817    817       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     820    820       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     915    915       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     936    936       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   LIPID         2      2       N-myristoyl glycine. {ECO:0000250}.
FT   VAR_SEQ       1     73       MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRT
FT                                TETGFNIFTQHDHFASCVEDGFEGDKTGGSSP -> MVLGT
FT                                VLLPPNSYGRDQDTSLCCLCTEASESALPDLT (in
FT                                isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:18810762}.
FT                                /FTId=VSP_004961.
FT   VAR_SEQ       1     52       MGQQVGRVGEAPGLQQPQPRGIRGSSAARPSGRRRDPAGRT
FT                                TETGFNIFTQH -> MVLGTVLLPPNSYGRDQDTSLCCLCT
FT                                EASESALPDLT (in isoform 3 and isoform
FT                                10). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_017112.
FT   VAR_SEQ      53     73       Missing (in isoform 6, isoform 7 and
FT                                isoform 8). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:18810762}.
FT                                /FTId=VSP_041772.
FT   VAR_SEQ     550    564       EEVAEELGRAASSSS -> EVLLHCANQTCITL (in
FT                                isoform 8).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041773.
FT   VAR_SEQ     565   1182       Missing (in isoform 8).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041774.
FT   VAR_SEQ     688    790       Missing (in isoform 4, isoform 5, isoform
FT                                7 and isoform 10).
FT                                {ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:18810762}.
FT                                /FTId=VSP_021308.
FT   VARIANT      78     78       R -> H (in dbSNP:rs55655202).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_055411.
FT   VARIANT      99     99       E -> Q (somatic mutation in a breast
FT                                cancer sample).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_055412.
FT   VARIANT     519    519       R -> I (somatic mutation in a lung
FT                                squamous cell carcinoma).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_055413.
FT   VARIANT     769    769       T -> S (in dbSNP:rs55892721).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_055414.
FT   VARIANT     930    930       K -> R (in dbSNP:rs17277288).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029232.
FT   VARIANT     946    946       V -> M (in dbSNP:rs28913889).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029233.
FT   VARIANT     996    996       P -> R (in dbSNP:rs28913890).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029234.
FT   VARIANT    1085   1085       S -> N (in dbSNP:rs28913891).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029235.
FT   VARIANT    1101   1101       T -> A (in dbSNP:rs28913892).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_029236.
FT   CONFLICT    343    344       NL -> TI (in Ref. 9; no nucleotide
FT                                entry). {ECO:0000305}.
FT   CONFLICT    435    435       T -> I (in Ref. 3; AK311045).
FT                                {ECO:0000305}.
FT   CONFLICT    981    981       K -> R (in Ref. 4; CAD98092).
FT                                {ECO:0000305}.
FT   HELIX       168    170       {ECO:0000244|PDB:4EIH}.
FT   STRAND      174    177       {ECO:0000244|PDB:4EIH}.
FT   HELIX       180    187       {ECO:0000244|PDB:4EIH}.
FT   STRAND      194    199       {ECO:0000244|PDB:4EIH}.
FT   STRAND      207    213       {ECO:0000244|PDB:4EIH}.
FT   STRAND      216    221       {ECO:0000244|PDB:4EIH}.
FT   STRAND      226    228       {ECO:0000244|PDB:2ECD}.
FT   STRAND      230    233       {ECO:0000244|PDB:4EIH}.
FT   STRAND      236    240       {ECO:0000244|PDB:4EIH}.
FT   HELIX       241    248       {ECO:0000244|PDB:4EIH}.
FT   STRAND      255    257       {ECO:0000244|PDB:4EIH}.
FT   STRAND      280    282       {ECO:0000244|PDB:3GVU}.
FT   HELIX       285    287       {ECO:0000244|PDB:3HMI}.
FT   STRAND      288    293       {ECO:0000244|PDB:3HMI}.
FT   HELIX       294    297       {ECO:0000244|PDB:3HMI}.
FT   STRAND      300    307       {ECO:0000244|PDB:3HMI}.
FT   HELIX       308    310       {ECO:0000244|PDB:3HMI}.
FT   STRAND      312    318       {ECO:0000244|PDB:3HMI}.
FT   HELIX       326    337       {ECO:0000244|PDB:3HMI}.
FT   STRAND      347    351       {ECO:0000244|PDB:3HMI}.
FT   STRAND      353    356       {ECO:0000244|PDB:3HMI}.
FT   STRAND      358    362       {ECO:0000244|PDB:3HMI}.
FT   HELIX       369    375       {ECO:0000244|PDB:3HMI}.
FT   TURN        378    380       {ECO:0000244|PDB:3HMI}.
FT   HELIX       383    402       {ECO:0000244|PDB:3HMI}.
FT   HELIX       412    414       {ECO:0000244|PDB:3HMI}.
FT   STRAND      415    417       {ECO:0000244|PDB:3HMI}.
FT   HELIX       419    421       {ECO:0000244|PDB:3HMI}.
FT   STRAND      423    425       {ECO:0000244|PDB:3HMI}.
FT   STRAND      435    437       {ECO:0000244|PDB:2XYN}.
FT   STRAND      438    440       {ECO:0000244|PDB:3GVU}.
FT   HELIX       449    451       {ECO:0000244|PDB:3HMI}.
FT   HELIX       454    459       {ECO:0000244|PDB:3HMI}.
FT   HELIX       464    479       {ECO:0000244|PDB:3HMI}.
FT   HELIX       491    493       {ECO:0000244|PDB:3HMI}.
FT   HELIX       494    499       {ECO:0000244|PDB:3HMI}.
FT   HELIX       512    521       {ECO:0000244|PDB:3HMI}.
FT   HELIX       526    528       {ECO:0000244|PDB:3HMI}.
FT   HELIX       532    545       {ECO:0000244|PDB:3HMI}.
FT   HELIX      1069   1071       {ECO:0000244|PDB:2KK1}.
FT   TURN       1076   1078       {ECO:0000244|PDB:2KK1}.
FT   HELIX      1080   1083       {ECO:0000244|PDB:2KK1}.
FT   HELIX      1086   1099       {ECO:0000244|PDB:2KK1}.
FT   HELIX      1106   1123       {ECO:0000244|PDB:2KK1}.
FT   HELIX      1124   1126       {ECO:0000244|PDB:2KK1}.
FT   HELIX      1130   1152       {ECO:0000244|PDB:2KK1}.
FT   STRAND     1155   1158       {ECO:0000244|PDB:2KK1}.
FT   HELIX      1165   1181       {ECO:0000244|PDB:2KK1}.
SQ   SEQUENCE   1182 AA;  128343 MW;  ED93869BC2B14FAA CRC64;
     MGQQVGRVGE APGLQQPQPR GIRGSSAARP SGRRRDPAGR TTETGFNIFT QHDHFASCVE
     DGFEGDKTGG SSPEALHRPY GCDVEPQALN EAIRWSSKEN LLGATESDPN LFVALYDFVA
     SGDNTLSITK GEKLRVLGYN QNGEWSEVRS KNGQGWVPSN YITPVNSLEK HSWYHGPVSR
     SAAEYLLSSL INGSFLVRES ESSPGQLSIS LRYEGRVYHY RINTTADGKV YVTAESRFST
     LAELVHHHST VADGLVTTLH YPAPKCNKPT VYGVSPIHDK WEMERTDITM KHKLGGGQYG
     EVYVGVWKKY SLTVAVKTLK EDTMEVEEFL KEAAVMKEIK HPNLVQLLGV CTLEPPFYIV
     TEYMPYGNLL DYLRECNREE VTAVVLLYMA TQISSAMEYL EKKNFIHRDL AARNCLVGEN
     HVVKVADFGL SRLMTGDTYT AHAGAKFPIK WTAPESLAYN TFSIKSDVWA FGVLLWEIAT
     YGMSPYPGID LSQVYDLLEK GYRMEQPEGC PPKVYELMRA CWKWSPADRP SFAETHQAFE
     TMFHDSSISE EVAEELGRAA SSSSVVPYLP RLPILPSKTR TLKKQVENKE NIEGAQDATE
     NSASSLAPGF IRGAQASSGS PALPRKQRDK SPSSLLEDAK ETCFTRDRKG GFFSSFMKKR
     NAPTPPKRSS SFREMENQPH KKYELTGNFS SVASLQHADG FSFTPAQQEA NLVPPKCYGG
     SFAQRNLCND DGGGGGGSGT AGGGWSGITG FFTPRLIKKT LGLRAGKPTA SDDTSKPFPR
     SNSTSSMSSG LPEQDRMAMT LPRNCQRSKL QLERTVSTSS QPEENVDRAN DMLPKKSEES
     AAPSRERPKA KLLPRGATAL PLRTPSGDLA ITEKDPPGVG VAGVAAAPKG KEKNGGARLG
     MAGVPEDGEQ PGWPSPAKAA PVLPTTHNHK VPVLISPTLK HTPADVQLIG TDSQGNKFKL
     LSEHQVTSSG DKDRPRRVKP KCAPPPPPVM RLLQHPSICS DPTEEPTALT AGQSTSETQE
     GGKKAALGAV PISGKAGRPV MPPPQVPLPT SSISPAKMAN GTAGTKVALR KTKQAAEKIS
     ADKISKEALL ECADLLSSAL TEPVPNSQLV DTGHQLLDYC SGYVDCIPQT RNKFAFREAV
     SKLELSLQEL QVSSAAAGVP GTNPVLNNLL SCVQEISDVV QR
//
